PortalPublikationenFront-line daratumumab-VTd versus standard-of-care in ASCT-e...

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

Standard

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. / Moreau, Philippe; Hebraud, Benjamin; Facon, Thierry; Leleu, Xavier; Hulin, Cyrille; Hashim, Mahmoud; Hu, Yannan; Caillot, Denis; Benboubker, Lofti; Zweegman, Sonja; Merz, Maximilian; Weisel, Katja; Salwender, Hans; Mai, Elias K; Goldschmidt, Hartmut; Bertsch, Uta; Vanquickelberghe, Véronique; Kampfenkel, Tobias; Boer, Carla de; Krotneva, Stanimira; Proskorovsky, Irina; He, Jianming; Lam, Annette; Lee, Charlene; Cote, Sarah; Sonneveld, Pieter.

in: IMMUNOTHERAPY-UK, Jahrgang 13, Nr. 2, 02.2021, S. 143-154.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Moreau, P, Hebraud, B, Facon, T, Leleu, X, Hulin, C, Hashim, M, Hu, Y, Caillot, D, Benboubker, L, Zweegman, S, Merz, M, Weisel, K, Salwender, H, Mai, EK, Goldschmidt, H, Bertsch, U, Vanquickelberghe, V, Kampfenkel, T, Boer, CD, Krotneva, S, Proskorovsky, I, He, J, Lam, A, Lee, C, Cote, S & Sonneveld, P 2021, 'Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison', IMMUNOTHERAPY-UK, Jg. 13, Nr. 2, S. 143-154. https://doi.org/10.2217/imt-2020-0266

APA

Moreau, P., Hebraud, B., Facon, T., Leleu, X., Hulin, C., Hashim, M., Hu, Y., Caillot, D., Benboubker, L., Zweegman, S., Merz, M., Weisel, K., Salwender, H., Mai, E. K., Goldschmidt, H., Bertsch, U., Vanquickelberghe, V., Kampfenkel, T., Boer, C. D., ... Sonneveld, P. (2021). Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. IMMUNOTHERAPY-UK, 13(2), 143-154. https://doi.org/10.2217/imt-2020-0266

Vancouver

Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M et al. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. IMMUNOTHERAPY-UK. 2021 Feb;13(2):143-154. https://doi.org/10.2217/imt-2020-0266

Bibtex

@article{38ab28cd47cb4914bccf68907f816185,
title = "Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison",
abstract = "Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.",
author = "Philippe Moreau and Benjamin Hebraud and Thierry Facon and Xavier Leleu and Cyrille Hulin and Mahmoud Hashim and Yannan Hu and Denis Caillot and Lofti Benboubker and Sonja Zweegman and Maximilian Merz and Katja Weisel and Hans Salwender and Mai, {Elias K} and Hartmut Goldschmidt and Uta Bertsch and V{\'e}ronique Vanquickelberghe and Tobias Kampfenkel and Boer, {Carla de} and Stanimira Krotneva and Irina Proskorovsky and Jianming He and Annette Lam and Charlene Lee and Sarah Cote and Pieter Sonneveld",
year = "2021",
month = feb,
doi = "10.2217/imt-2020-0266",
language = "English",
volume = "13",
pages = "143--154",
journal = "IMMUNOTHERAPY-UK",
issn = "1750-743X",
publisher = "Future Medicine Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

AU - Moreau, Philippe

AU - Hebraud, Benjamin

AU - Facon, Thierry

AU - Leleu, Xavier

AU - Hulin, Cyrille

AU - Hashim, Mahmoud

AU - Hu, Yannan

AU - Caillot, Denis

AU - Benboubker, Lofti

AU - Zweegman, Sonja

AU - Merz, Maximilian

AU - Weisel, Katja

AU - Salwender, Hans

AU - Mai, Elias K

AU - Goldschmidt, Hartmut

AU - Bertsch, Uta

AU - Vanquickelberghe, Véronique

AU - Kampfenkel, Tobias

AU - Boer, Carla de

AU - Krotneva, Stanimira

AU - Proskorovsky, Irina

AU - He, Jianming

AU - Lam, Annette

AU - Lee, Charlene

AU - Cote, Sarah

AU - Sonneveld, Pieter

PY - 2021/2

Y1 - 2021/2

N2 - Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

AB - Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

U2 - 10.2217/imt-2020-0266

DO - 10.2217/imt-2020-0266

M3 - SCORING: Journal article

C2 - 33228440

VL - 13

SP - 143

EP - 154

JO - IMMUNOTHERAPY-UK

JF - IMMUNOTHERAPY-UK

SN - 1750-743X

IS - 2

ER -